Amgen Panitumumab Could See Third Quarter Approval For Third-Line Colorectal Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen and development partner Abgenix are seeking priority review for the epidermal growth factor inhibitor.